Replies to post #101 on SciClone Pharmaceuticals, Inc. (SCLN)

[surf1944]

SciClone Pharmaceuticals (SCLN): The company, which trades in a 52-week range of $3.41 (52-week low) to $7.45 (52-week high), has traded up roughly 4.8% over the last few trading sessions and could continue to demonstrate similar behavior throughout the second half of the year. One the key catalysts for potential investors would be projected quarterly growth when compared to the S&P 500. Currently, SCLN is expected to grow at rate of 200% for the quarter, which is 19.41 times that of the S&P 500, which is expected to only grow 10.3% for the quarter.

For potential investors looking to establish a position in SCLN, the company is expected to post a profit of $0.18/share on revenue of $41.98 million for the second quarter. Given the fact that the company has surpassed analysts' estimates in the last four quarters, another earnings estimate beat of at least 15% would positively contribute to the company's growth. In terms of establishing a position at these levels, a small- to medium-sized position would be acceptable at current levels, and more shares should be added as earnings announcements approach.

http://seekingalpha.com/article/705781-3-promising-pharma-companies-projected-to-grow-5-times-faster-than-the-s-p-500?source=yahoo